Takeaway

• Long-acting injectable (LAI) antipsychotic treatment does not appear to prevent more treatment discontinuations or offer an advantage over oral medications in patients with early-phase schizophrenia.

Why this matters

• Discuss LAI treatment with patients to determine if the benefits (sustained cognitive function, suicide reduction, lower rehospitalisation risk) outweigh the need...